A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks

Pfizer

Status and phase

Terminated

Phase 2

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: PF-00915275

Study type

Interventional

Funder types

Industry

Identifiers

NCT00427401

A8441003

Details and patient eligibility

About

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PF-00915275 following administration to adult human subjects with T2DM for 4-weeks. The primary end point is glucose lowering (24 hour mean glucose concentration).

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Type 2 diabetes mellitus
HbA1c > 7.5%.

Exclusion criteria

Recent (within the past 12 months) evidence or history of unstable concomitant disease.
Treatment with any oral hypoglycemic agent within 3 months before enrollment.
The exception to these criteria is that subjects who are currently taking metformin hydrochloride, in a stable dose (that is no changes in dose) for treatment of their diabetes within the past 3 months or longer of enrollment may participate.